Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...

Research has suggested that strawberries could have a positive impact on cognitive health and potentially reduce someone's ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

A drug that can slow the progression of Alzheimer's disease has been blocked for use on the NHS due to cost concerns.

Kisunla, also known as donanemab, works by removing a sticky protein from the brain believed to cause Alzheimer’s disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...